ArticleCureus2025
Rheumatic Heart Disease and Contraception Use in Ethiopia: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Women of reproductive age with rheumatic heart disease (RHD) face a high risk of cardiovascular complications during pregnancy. Consequently, preconception counseling and contraception are routinely recommended for all women of reproductive age. In Ethiopia, there are no data available regarding contraception coverage among women with RHD. Objectives The aims of this study were to examine the prevalence of contraceptive use, investigate the most common methods, and identify factors influencing contraception use among reproductive-age women with RHD in Ethiopia. Methodology The study included patients who were followed at a tertiary hospital between January 1, 2017, and October 30, 2018. A total of 359 women aged 15 to 49 years with RHD were randomly selected and evaluated using standardized questionnaires and chart reviews. Chi-square and logistic regression analyses were utilized to measure associations. A p-value of ≤0.05 was deemed significant, with a 95% confidence interval. Results The mean age was 30.96 ±7.84 years. Of the patients, 219 (61%) were unemployed, and only 92 (25%) had higher education. Of the 241 (67%) who had severe RHD, 205 (57%) had combined valve lesions, 76 (21.2%) had isolated mitral stenosis, and 62 (17.3%) had isolated mitral regurgitation. Of the total of 359 patients, 300 (83.6%) had symptoms; 241 (67.1%) were class IV per the modified World Health Organization (mWHO) cardiovascular risk assessment, and the rest, 118 (32.9%), were class III. A total of 139 (38.9%) and 112 (31.3%) were on warfarin and angiotensin-converting enzyme inhibitors, respectively. However, only 149 (41.5%) were on contraceptives, and among non-users, 226 (63%) reported no counseling. Injectables were the most used contraceptive, followed by intrauterine devices and oral pills. Marital status (OR: 3.26, 95% CI: 2.03-5.22, P < 0.001) and employment (OR: 3.82, 95% CI: 1.58-9.24, P = 0.003) were the only two statistically significant factors associated with contraception use. Conclusion Contraception use was low among women with RHD in Ethiopia. Patients with contraindications for pregnancy were not provided with adequate counseling and contraception. Additionally, those who were using contraception were on ineffective methods. Further action is needed to improve contraception use among women with RHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.